| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Chongqing Pharscin Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.58 |
| 52 Week High | CN¥20.50 |
| 52 Week Low | CN¥9.82 |
| Beta | -0.29 |
| 11 Month Change | 9.25% |
| 3 Month Change | -8.86% |
| 1 Year Change | -24.05% |
| 33 Year Change | 10.59% |
| 5 Year Change | -11.36% |
| Change since IPO | 108.28% |
Recent News & Updates
Shareholder Returns
| 002907 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 9.3% | 6.4% | 0.4% |
| 1Y | -24.0% | -10.6% | -21.0% |
Return vs Industry: 002907 underperformed the CN Pharmaceuticals industry which returned -10.6% over the past year.
Return vs Market: 002907 underperformed the CN Market which returned -21% over the past year.
Price Volatility
| 002907 volatility | |
|---|---|
| 002907 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 002907 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002907's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,411 | Xiaoying Liu | www.pharscin.com |
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, soft capsules, powder injections, freeze-dried powders, injections, chemical raw materials, and small volume injections. It provides its products for the treatment of CNS, digestion, otolaryngology, oncology, cardiovascular, and cerebrovascular related diseases.
Chongqing Pharscin Pharmaceutical Co., Ltd. Fundamentals Summary
| 002907 fundamental statistics | |
|---|---|
| Market cap | CN¥5.67b |
| Earnings (TTM) | CN¥42.95m |
| Revenue (TTM) | CN¥732.40m |
132.0x
P/E Ratio7.7x
P/S RatioIs 002907 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002907 income statement (TTM) | |
|---|---|
| Revenue | CN¥732.40m |
| Cost of Revenue | CN¥327.85m |
| Gross Profit | CN¥404.55m |
| Other Expenses | CN¥361.60m |
| Earnings | CN¥42.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 55.24% |
| Net Profit Margin | 5.86% |
| Debt/Equity Ratio | 0% |
How did 002907 perform over the long term?
See historical performance and comparison